GH Research
a phase dose ranging study to assess safety and effects of a vaporized formulation in healthy volunteers | GH Research
Company
Deck Type
Deck date
October 2022
Slide
1 of 6
Related slides by other companies
NeuroSense Therapeutics
Investor Presentation
January 2024
met primary and exploratory in phase a study | NeuroSense Therapeutics
NeuroSense Therapeutics
Investor Presentation
December 2023
met primary and exploratory in phase a study | NeuroSense Therapeutics
NeuroSense Therapeutics
Investor Presentation
June 2023
phase trial design | NeuroSense Therapeutics
Other recent decks by GH Research
See all presentations (4 decks)
Investor Presentation
November 2023
Investor Presentation
May 2023
Investor Presentation
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights